{
    "organizations": [],
    "uuid": "cb7bf4d8ab7c217c1001b763e220d04ca07dc920",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-astrazeneca-disappointed-by-data-f/brief-astrazeneca-disappointed-by-data-from-arctic-trial-in-third-line-non-small-cell-lung-cancer-idUSFWN1S106S",
    "ord_in_thread": 0,
    "title": "BRIEF-AstraZeneca disappointed by data from Arctic trial in third-line non-small cell lung cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " AstraZeneca PLC:\n* REPORTS RESULTS FROM ARCTIC TRIAL IN THIRD-LINE NON-SMALL CELL LUNG CANCER\n* WHILE WE ARE DISAPPOINTED THAT COMBINATION OF IMFINZI PLUS TREMELIMUMAB DID NOT RESULT IN A STATISTICALLY-SIGNIFICANT SURVIVAL BENEFIT IN THIS HEAVILY PRE-TREATED PATIENT POPULATION, WE ARE ENCOURAGED BY ACTIVITY OF IMFINZI MONOTHERAPY OBSERVED IN THIS TRIAL\n* FULL DATA FROM ARCTIC TRIAL WILL BE PRESENTED AT A FORTHCOMING MEDICAL MEETING Source text for Eikon: Further company coverage: (London Newsroom)\n ",
    "published": "2018-04-24T14:17:00.000+03:00",
    "crawled": "2018-04-25T14:23:47.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "astrazeneca",
        "plc",
        "report",
        "result",
        "arctic",
        "trial",
        "cell",
        "lung",
        "cancer",
        "disappointed",
        "combination",
        "imfinzi",
        "plus",
        "tremelimumab",
        "result",
        "survival",
        "benefit",
        "heavily",
        "patient",
        "population",
        "encouraged",
        "activity",
        "imfinzi",
        "monotherapy",
        "observed",
        "trial",
        "full",
        "data",
        "arctic",
        "trial",
        "presented",
        "forthcoming",
        "medical",
        "meeting",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "london",
        "newsroom"
    ]
}